FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384154663> ?p ?o ?g. }

• W4384154663 endingPage "962" @default.
• W4384154663 startingPage "954" @default.
• W4384154663 abstract "Background and Aim: Benralizumab is a biologic add-on treatment for severe eosinophilic asthma that can reduce the rate of asthma exacerbations, but data on the associated medical utilization are scarce. This retrospective study evaluated the economic value of benralizumab by analyzing healthcare resource utilization (HRU) and medical costs in a large patient population in the US.Methods: Insurance claims data (11/2016–6/2020) were analyzed. A pre–post design was used to compare asthma exacerbation rates, medical HRU and medical costs in the 12 months pre vs. post index (day after benralizumab initiation). Patients were aged ≥12 years, with ≥2 records of benralizumab and ≥2 asthma exacerbations pre index, and constituted non-mutually exclusive cohorts: biologic-naïve, biologic-experienced (switched from omalizumab or mepolizumab to benralizumab), or with extended follow-up (18 or 24 months).Results: In all cohorts (mean age 51–53 years; 67%–70% female; biologic-naïve, N = 1,292; biologic-experienced, N = 349; 18-month follow-up, N = 419; 24-month follow-up, N = 156), benralizumab treatment reduced the rate of asthma exacerbation by 53%–68% (p < 0.001). In the biologic-naïve cohort, inpatient admissions decreased by 58%, emergency department visits by 54%, and outpatient visits by 58% post index (all p < 0.001), with similar reductions in exacerbation-related medical HRU in other cohorts. Exacerbation-related mean total medical costs decreased by 51% in the biologic-naïve cohort ($4691 pre-index, $2289 post-index), with cost differences ranging from 16% to 64% across other cohorts (prior omalizumab: $2686 to $1600; prior mepolizumab: $5990 to $5008; 18-month: $3636 to $1667; 24-month: $4014 to $1449; all p < 0.001). Medical HRU and cost reductions were durable, decreasing by 64% in year 1 and 66% in year 2 in the 24 month follow-up cohort.Conclusion: Patients treated with benralizumab with prior exacerbations experienced reductions in asthma exacerbations and exacerbation-related medical HRU and medical costs regardless of prior biologic use, with the benefits observed for up to 24 months after treatment initiation." @default.
• W4384154663 created "2023-07-14" @default.
• W4384154663 creator A5012377810 @default.
• W4384154663 creator A5015972111 @default.
• W4384154663 creator A5021604960 @default.
• W4384154663 creator A5024603498 @default.
• W4384154663 creator A5065311807 @default.
• W4384154663 creator A5065858299 @default.
• W4384154663 creator A5067253265 @default.
• W4384154663 creator A5074273683 @default.
• W4384154663 creator A5082436413 @default.
• W4384154663 date "2023-07-31" @default.
• W4384154663 modified "2023-09-25" @default.
• W4384154663 title "Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study" @default.
• W4384154663 cites W1790252094 @default.
• W4384154663 cites W2469356234 @default.
• W4384154663 cites W2475207018 @default.
• W4384154663 cites W2553441977 @default.
• W4384154663 cites W2637940744 @default.
• W4384154663 cites W2756181502 @default.
• W4384154663 cites W2910131302 @default.
• W4384154663 cites W2955979864 @default.
• W4384154663 cites W2971454564 @default.
• W4384154663 cites W2974946068 @default.
• W4384154663 cites W3095829027 @default.
• W4384154663 cites W3145782157 @default.
• W4384154663 cites W3171474935 @default.
• W4384154663 cites W3178363436 @default.
• W4384154663 cites W3181891508 @default.
• W4384154663 cites W3201610498 @default.
• W4384154663 cites W3203630269 @default.
• W4384154663 cites W4200182448 @default.
• W4384154663 cites W4212936424 @default.
• W4384154663 cites W4213350887 @default.
• W4384154663 cites W4214911843 @default.
• W4384154663 cites W4220967255 @default.
• W4384154663 cites W4226102981 @default.
• W4384154663 cites W4281560606 @default.
• W4384154663 cites W4283120210 @default.
• W4384154663 cites W4283795206 @default.
• W4384154663 cites W4327684002 @default.
• W4384154663 cites W4367856540 @default.
• W4384154663 doi "https://doi.org/10.1080/13696998.2023.2236867" @default.
• W4384154663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37441729" @default.
• W4384154663 hasPublicationYear "2023" @default.
• W4384154663 type Work @default.
• W4384154663 citedByCount "0" @default.
• W4384154663 crossrefType "journal-article" @default.
• W4384154663 hasAuthorship W4384154663A5012377810 @default.
• W4384154663 hasAuthorship W4384154663A5015972111 @default.
• W4384154663 hasAuthorship W4384154663A5021604960 @default.
• W4384154663 hasAuthorship W4384154663A5024603498 @default.
• W4384154663 hasAuthorship W4384154663A5065311807 @default.
• W4384154663 hasAuthorship W4384154663A5065858299 @default.
• W4384154663 hasAuthorship W4384154663A5067253265 @default.
• W4384154663 hasAuthorship W4384154663A5074273683 @default.
• W4384154663 hasAuthorship W4384154663A5082436413 @default.
• W4384154663 hasBestOaLocation W43841546631 @default.
• W4384154663 hasConcept C126322002 @default.
• W4384154663 hasConcept C167135981 @default.
• W4384154663 hasConcept C187212893 @default.
• W4384154663 hasConcept C194828623 @default.
• W4384154663 hasConcept C2776042228 @default.
• W4384154663 hasConcept C2777014857 @default.
• W4384154663 hasConcept C2777037409 @default.
• W4384154663 hasConcept C2777832160 @default.
• W4384154663 hasConcept C2779185760 @default.
• W4384154663 hasConcept C2908647359 @default.
• W4384154663 hasConcept C2909082789 @default.
• W4384154663 hasConcept C71924100 @default.
• W4384154663 hasConcept C72563966 @default.
• W4384154663 hasConcept C99454951 @default.
• W4384154663 hasConceptScore W4384154663C126322002 @default.
• W4384154663 hasConceptScore W4384154663C167135981 @default.
• W4384154663 hasConceptScore W4384154663C187212893 @default.
• W4384154663 hasConceptScore W4384154663C194828623 @default.
• W4384154663 hasConceptScore W4384154663C2776042228 @default.
• W4384154663 hasConceptScore W4384154663C2777014857 @default.
• W4384154663 hasConceptScore W4384154663C2777037409 @default.
• W4384154663 hasConceptScore W4384154663C2777832160 @default.
• W4384154663 hasConceptScore W4384154663C2779185760 @default.
• W4384154663 hasConceptScore W4384154663C2908647359 @default.
• W4384154663 hasConceptScore W4384154663C2909082789 @default.
• W4384154663 hasConceptScore W4384154663C71924100 @default.
• W4384154663 hasConceptScore W4384154663C72563966 @default.
• W4384154663 hasConceptScore W4384154663C99454951 @default.
• W4384154663 hasIssue "1" @default.
• W4384154663 hasLocation W43841546631 @default.
• W4384154663 hasLocation W43841546632 @default.
• W4384154663 hasLocation W43841546633 @default.
• W4384154663 hasOpenAccess W4384154663 @default.
• W4384154663 hasPrimaryLocation W43841546631 @default.
• W4384154663 hasRelatedWork W1189286865 @default.
• W4384154663 hasRelatedWork W1957770986 @default.
• W4384154663 hasRelatedWork W1985426726 @default.
• W4384154663 hasRelatedWork W2031384963 @default.
• W4384154663 hasRelatedWork W2050460305 @default.
• W4384154663 hasRelatedWork W2386381627 @default.

• next